title: D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure.
abstract: Six participants currently in opioid maintenance treatment were trained to distinguish between naloxone (0.15 mg/70 kg, intramuscularly [i.m.]) and placebo under an instructed novel-response drug-discrimination procedure. Doses of the partial glycine agonist D-cycloserine (0-500 mg/70 kg, per os [P.O.]) alone and combined with naloxone (0.15 mg/70 kg) were then tested. D-cycloserine alone produced minimal drug-appropriate responding, no significant changes in self-reported effects, and increases only in systolic blood pressure. When combined with the naloxone, D-cycloserine partially attenuated naloxone-appropriate responding. D-cycloserine attenuated naloxone-induced increases in visual analog scale ratings of "like naloxone" and scores on the Lysergic Acid Diethyl Amide subscale of the Addiction Research Center Inventory (D. R. Jasinski, 1977; W. R. Martin, J. W. Sloan, J. D. Sapiro, & D. R. Jasinski, 1971). Naloxone attenuated D-cycloserine-induced increases in systolic blood pressure. These results suggest that D-cycloserine at doses up to 500 mg/70 kg may have some limited usefulness in relieving symptoms of opioid withdrawal.
authors.affiliation: Department of Psychiatry, Yale School of Medicine and Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut 06516, USA. alison.oliveto@yale.edu
authors.forename: Alison
authors.initials: A
authors.lastname: Oliveto
authors.forename: Thania
authors.initials: T
authors.lastname: Benios
authors.forename: Kishorchandra
authors.initials: K
authors.lastname: Gonsai
authors.forename: Alan
authors.initials: A
authors.lastname: Feingold
authors.forename: James
authors.initials: J
authors.lastname: Poling
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Kosten
mesh_terms: D000328:Adult; D000963:Antimetabolites / Q000494:pharmacology*; D003523:Cycloserine / Q000494:pharmacology*; D004192:Discrimination, Psychological / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D009293:Opioid-Related Disorders / Q000523:psychology*; D010147:Pain Measurement
chemical_list: D000963:Antimetabolites; D009292:Narcotic Antagonists; D009270:Naloxone; D003523:Cycloserine